CRIS Current Research Information System

LANZA, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 9.026
NA - Nord America 6.394
EU - Europa 2.627
SA - Sud America 734
Continente sconosciuto - Info sul continente non disponibili 662
AF - Africa 178
OC - Oceania 9
Totale 19.630
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.190
CN - Cina 2.496
SG - Singapore 2.437
VN - Vietnam 2.063
IT - Italia 1.094
HK - Hong Kong 724
BR - Brasile 549
KR - Corea 384
DE - Germania 258
GB - Regno Unito 255
IN - India 201
BD - Bangladesh 186
FR - Francia 174
JP - Giappone 166
NL - Olanda 154
SE - Svezia 132
FI - Finlandia 117
CA - Canada 105
AR - Argentina 88
RU - Federazione Russa 78
IE - Irlanda 74
PH - Filippine 56
UA - Ucraina 52
MX - Messico 51
ID - Indonesia 48
TH - Thailandia 43
CH - Svizzera 42
CI - Costa d'Avorio 37
IQ - Iraq 37
ZA - Sudafrica 37
BG - Bulgaria 35
ES - Italia 35
TR - Turchia 31
TW - Taiwan 30
PL - Polonia 26
EC - Ecuador 21
PK - Pakistan 21
JO - Giordania 19
UZ - Uzbekistan 19
CL - Cile 18
SC - Seychelles 18
EE - Estonia 17
TG - Togo 17
AT - Austria 16
PY - Paraguay 16
SA - Arabia Saudita 15
CO - Colombia 14
VE - Venezuela 14
NG - Nigeria 13
CR - Costa Rica 12
MA - Marocco 12
BE - Belgio 11
AE - Emirati Arabi Uniti 10
JM - Giamaica 10
KE - Kenya 10
LT - Lituania 10
TN - Tunisia 9
AU - Australia 8
GR - Grecia 7
MY - Malesia 7
EG - Egitto 6
KZ - Kazakistan 6
UY - Uruguay 6
ET - Etiopia 5
NP - Nepal 5
RO - Romania 5
HN - Honduras 4
HR - Croazia 4
MD - Moldavia 4
OM - Oman 4
PE - Perù 4
SN - Senegal 4
AL - Albania 3
AZ - Azerbaigian 3
BB - Barbados 3
BO - Bolivia 3
BS - Bahamas 3
BY - Bielorussia 3
CZ - Repubblica Ceca 3
DK - Danimarca 3
PR - Porto Rico 3
PS - Palestinian Territory 3
PT - Portogallo 3
SK - Slovacchia (Repubblica Slovacca) 3
SV - El Salvador 3
DZ - Algeria 2
GE - Georgia 2
GH - Ghana 2
HU - Ungheria 2
IL - Israele 2
IS - Islanda 2
NI - Nicaragua 2
PA - Panama 2
SY - Repubblica araba siriana 2
XK - ???statistics.table.value.countryCode.XK??? 2
AI - Anguilla 1
AM - Armenia 1
CG - Congo 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
Totale 18.950
Salva come PNG Salva come JPEG
Città #
Singapore 1.560
Hefei 807
Hong Kong 686
Ho Chi Minh City 515
Hanoi 450
Ashburn 435
Beijing 430
San Jose 428
Seoul 355
Boardman 302
Santa Clara 277
Los Angeles 189
Fairfield 173
Southend 166
Bologna 143
Tokyo 139
New York 124
Dallas 117
Council Bluffs 110
Chandler 108
Houston 97
Da Nang 94
Helsinki 94
Milan 92
Haiphong 80
Woodbridge 78
Frankfurt am Main 77
Lauterbourg 77
Dublin 75
Seattle 74
Bengaluru 72
Wilmington 69
Ann Arbor 62
Buffalo 62
São Paulo 54
Cambridge 53
Chicago 53
Rome 53
Guangzhou 50
Princeton 46
Shanghai 46
Dong Ket 39
Phoenix 39
Abidjan 37
Jacksonville 37
Florence 36
Sofia 33
Munich 30
Turin 29
Bern 28
Tongling 28
Biên Hòa 26
Brooklyn 26
Hải Dương 25
Jakarta 25
Redondo Beach 25
Padova 24
Denver 23
Genoa 23
Naples 23
Nuremberg 23
San Francisco 23
Toronto 23
Ha Long 21
Mexico City 21
Montreal 21
Nanjing 21
Quận Bình Thạnh 21
Amsterdam 20
Baghdad 20
Rio de Janeiro 20
Zhengzhou 20
Amman 19
Bắc Ninh 19
Changsha 19
Rimini 18
Tianjin 18
Warsaw 18
Westminster 18
Lappeenranta 17
Lomé 17
Orem 17
Tashkent 17
Thái Nguyên 17
Las Vegas 16
Salt Lake City 16
Can Tho 15
Elk Grove Village 15
Hangzhou 15
Ninh Bình 15
Shenyang 15
Shenzhen 15
Xi'an 15
Atlanta 14
Jinan 14
Manchester 14
Paris 14
Bangkok 13
Bắc Giang 13
Fort Worth 13
Totale 10.228
Salva come PNG Salva come JPEG
Nome #
MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia 2.038
Stem Cells 371
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study 287
AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia 258
A simple method for identifying bone marrow mesenchymal stromal cells with a high immunosuppressive potential. 256
Isolation of stem cell populations with trophic and immunoregulatory functions from human intestinal tissues: potential for cell therapy in inflammatory bowel disease. 242
A decreased positivity for CD90 on human mesenchymal stromal cells (MSCs) is associated with a loss of immunosuppressive activity by MSCs. 239
Cellule staminali. Embrionali, mesenchimali, emopoietiche, intestinali, cardiovascolari, muscolari, nervose e placentari 234
Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents 212
A functional role for soluble HLA-G antigens in immune modulation mediated by mesenchymal stromal cells. 191
Umbilical cord blood CD34(+)cell-derived progeny produces human leukocyte antigen-G molecules with immuno-modulatory functions. 189
Uncovering the expression of circPVT1 in the extracellular vesicles of acute myeloid leukemia patients 185
Upfront intensive treatment analysis of the Italian Cohort Study on FLT3‐mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real‐life setting 178
Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia 174
Azacitidine Low-Dose Schedule In Low-Risk Myelodysplastic Syndromes. Preliminary Results of a Multicenter Phase II Study 164
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study 163
Description of 18 PNH patients with prevalent GPI‐deficient monocytes. An Italian survey 162
Multiple Myeloma: The Role of Autologous Stem Cell Transplantation in the Era of Immunotherapy 162
Identification of Novel Potential Predisposing Variants in Familial Acute Myeloid Leukemia 160
Analysis of 339 pregnancies in 181 women with 13 different forms of inherited thrombocytopenia. 157
Acute Myeloid Leukemia: Updates on Diagnosis, Treatment and Management 156
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies 154
Azacitidine low-dose schedule in low-risk myelodysplastic syndromes. Clinical results of a multicenter phase II study 150
Novel insights and therapeutic approaches in secondary AML 149
Vinciamo la vita. Oltre la cura il benessere. Un percorso di lungo periodo nell'alleanza medico paziente-famiglia. 148
INO-CD22: A Multi-Center, Real-Life Study on Inotuzumab-Ozogamicin Safety and Effectiveness in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia 147
Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin 142
European Data on Stem Cell Mobilization with Plerixafor in Non-Hodgkin’s Lymphoma, Hodgkin’s Lymphoma and Multiple Myeloma Patients. A Subgroup Analysis of the European Consortium of Stem Cell Mobilization. 142
Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV 139
CD22 expression in b-cell acute lymphoblastic leukemia: Biological significance and implications for inotuzumab therapy in adults 136
PNH clones prevalence study in ph-negative myeloproliferative neoplasms: a multicenter Italian study 135
Low WT1 Expression Identifies a Subset of Acute Myeloid Leukemia with a Distinct Genotype 133
Comparative clinical efficacy and safety of biosimilar ABP 959 and eculizumab reference product in patients with paroxysmal nocturnal hemoglobinuria 132
Long-Term Outcome of Peripheral Blood Autologous Stem Cell Transplantation (AutoSCT) for De Novo Acute Myeloid Leukemia in Patients Achieving First Complete Remission after One Vs Two Induction Courses: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) 132
New Horizons in Immunology and Immunotherapy of Acute Leukemias and Related Disorders 128
Five‐Year Real‐World Safety of Inotuzumab Ozogamicin Before Hematopoietic Stem Cell Transplantation in B‐Cell Precursor Acute Lymphoblastic Leukemia 127
Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model 124
Long-term survival can be achieved in a significant fraction of older patients with core binding factor acute myeloid leukemia treated with intensive chemotherapy 122
Autologous stem cell transplantation (ASCT) for acute myeloid leukemia in patients in first complete remission after one versus two induction courses: A study from the ALWP of the EBMT 119
Higher BMI is not a barrier to stem cell mobilization with standard doses of plerixafor and G-CSF. 118
Low-Dose Cyclophosphamide versus Intermediate-High-Dose Cyclophosphamide versus Granulocyte Colony-Stimulating Factor Alone for Stem Cell Mobilization in Multiple Myeloma in the Era of Novel Agents: A Multicenter Retrospective Study 117
Efficacy and Safety of Biosimilar Candidate ABP 959 As Compared with Eculizumab Reference Product in Paroxysmal Nocturnal Hemoglobinuria 116
Pharmacological inhibition of wip1 sensitizes acute myeloid leukemia cells to the mdm2 inhibitor nutlin-3a 116
Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo italianoTrapianto di Midollo Osseo. 115
Development of adaptive immune effector therapies in solid tumors 113
Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide. 112
ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol 108
Results of the 6-Year Follow- up of the Gimema AML1310 Trial: A Risk-Adapted, MRD-Directed Therapy for Young Adults with Newly Diagnosed Acute Myeloid Leukemia 108
Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a 106
A REGISTRY-BASED, OBSERVATIONAL SAFETY STUDY OF INOTUZUMAB OZOGAMICIN (INO) IN PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PROCEEDING TO HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) 101
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients 98
null 97
Postremission Consolidation by Autologous Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia in First Complete Remission (CR) and Negative Implications for Subsequent Allogeneic HCT in Second CR: A Study by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) 96
Autologous stem cell transplantation for adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. A study by the Acute Leukemia Working Party of the EBMT 96
The oldest case of lymphoma? Insights from a XIII century fresco 96
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study 95
Pivotal Results of SELECT-MDS-1 Phase 3 Study of Tamibarotene with Azacitidine in Newly Diagnosed Higher-Risk MDS 94
Targeted Therapies and Druggable Genetic Anomalies in Acute Myeloid Leukemia: From Diagnostic Tools to Therapeutic Interventions 93
CD34+ cell dose effects on clinical outcomes after T-cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) 93
Alloreactivity: the Janus-face of hematopoietic stem cell transplantation 93
PNH CLONES PREVALENCE STUDY IN PH-NEGATIVE MYELOPROLIFERATIVE DISORDERS 92
The Circular Life of Human CD38: From Basic Science to Clinics and Back 92
Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed/refractory acute myeloid leukaemia: A subanalysis of the AVALON study 92
RISK-ADAPTED MRD-DIRECTED THERAPY FOR YOUNG ACUTE MYELOID LEUKEMIA ADULTS: 6-YEAR UPDATE OF THE GIMEMA AML1310 TRIAL 91
Veno-Occlusive Disease Risk and Other Outcomes in Patients with B-Cell Precursor Acute Lymphoblastic Leukemia Who Received Inotuzumab Ozogamicin and Proceeded to Hematopoietic Stem Cell Transplantation: A Registry-Based, Observational Study 91
Olutasidenib (FT-2102) in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Acute Myeloid Leukemia 90
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies 88
Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study 86
Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3 internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation 83
Lenalidomide plus rituximab for the initial treatment of elderly frail patients with DLBCL: the FIL_ReRi Phase 2 Study 83
A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity-score weighted multicenter approach 82
Lack of efficacy of convalescent plasma in COVID-19 patients with concomitant hematological malignancies: An Italian retrospective study 82
A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi 81
null 81
null 77
null 76
Ziftomenib in Relapsed or Refractory NPM1-Mutated AML 75
Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients 74
Expression of the immunoglobulin superfamily cell membrane adhesion molecule Cd146 in acute leukemia 72
Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency 71
MRD Assessment in Patients With Acute Myeloid Leukemia Aged ≥ 60 Years Treated With a 10‐Day Decitabine Schedule Versus Intensive Chemotherapy in the AML21 Study 66
Maimonide. Origini storiche e percorsi di umanizzazione della cura 66
Overview on novel strategies and current guidelines for hematopoietic stem cell mobilisation and collection 66
Real life use of ravulizumab in Italian patients with paroxysmal nocturnal hemoglobinuria: evidence from the REACTION observational study 65
The Sorafenib plus Nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of the FLT3 and p53 status 64
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia 64
Growing adoption of pharmacologic maintenance therapy after allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a survey on behalf of the EBMT acute leukemia working party 63
Aberrant expression of HLA-DR antigen by bone marrow-derived mesenchymal stromal cells from patients affected by acute lymphoproliferative disorders 63
Isolamento e caratterizzazione immunofenotipica di cellule non-emopoietiche presenti in versamenti ascitici e pleurici di pazienti con malattie ematologiche 62
Novel approaches for hematopoietic stem cell mobilisation and collection need to be assessed for qualification and validation to accomplish the proper requirements of their intended purpose 61
Ibrutinib: from bench side to clinical implications 61
Individual quality assessment of autografting by probability estimation for clinical endpoints: a prospective validation study from the European group for blood and marrow transplantation 60
CD123 (Interleukin 3 receptor a chain) 58
Allogeneic transplantation for AML aged>= 70 years. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) 57
Cytogenetic and molecular cytogenetic profile of bone marrow-derived mesenchymal stromal cells in chronic and acute lymphoproliferative disorders 56
Medicine & Science Journal: a new multidisciplinary journal to fill the knowledge gaps in medical sciences through preclinical and clinical evidence 56
Therapeutic Use of Convalescent Plasma in COVID-19 Infected Patients with Concomitant Hematological Disorders 56
Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia 55
A report from the SIdEM: Italy 54
Issue highlights—November 2024 54
Totale 13.684
Salva come PNG Salva come JPEG
Categoria #
all - tutte 59.620
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 59.620
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022500 79 3 31 29 40 30 18 35 14 50 99 72
2022/2023932 50 69 35 61 34 37 12 149 165 132 92 96
2023/2024650 35 61 66 58 75 93 36 50 34 64 38 40
2024/20253.897 91 272 318 208 591 144 403 95 121 326 340 988
2025/202612.221 1.012 1.548 1.086 859 691 320 672 382 1.887 985 2.413 366
2026/2027309 309 0 0 0 0 0 0 0 0 0 0 0
Totale 19.630